Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double‐blind, placebo‐controlled trial

Yoon, Jae Sung; Sohn, Woon Mok; Lee, Oh Young; Lee, Sang Pyo; Lee, Kang Nyeong; Jun, Dae Won; Lee, Hang Lak; Yoon, Byung Chul; Choi, Ho Soon; Chung, Won-Seok; Seo, Jae Gu

doi:10.1111/jgh.12322

Cited by 139 publications

(144 citation statements)

References 41 publications

Supporting

Mentioning

136

Contrasting

Unclassified

Order By: Relevance

“…On the other hand, individuals with intestinal diseases may benefit from consumption of probiotics, and the effects may be more pronounced than in other individuals. A study on patients with irritable bowel syndrome (IBS) showed similar results, as probiotic supplementation increased the faecal counts of lactobacilli and bifidobacteria, but counts for Clostridium species and Escherichia coli subgroup remained the same 34 . Despite no change in the abundances of pathogenic groups, patients still experienced significant relief from the IBS symptoms.…”

Section: Parameter † Baselinesupporting

confidence: 54%

Effects of a probiotic preparation on the human faecal microflora and biochemical and haematological parameters

Lan

Hsieh²,

Tsai

et al. 2015

ScienceAsia

View full text Add to dashboard Cite

ABSTRACT:The aim of this study was to investigate the effects of supplementation of a probiotic preparation PROBIO-C containing Lactobacillus acidophilus, Bifidobacterium longum, L. rhamnosus, and Streptococcus thermophilus on the intestinal microflora of healthy volunteers and the effects on biochemical and haematological measurements. In vitro analyses, which included acid and bile salts tolerance and adhesion tests, were performed first. Probiotic bacteria in PROBIO-C demonstrated adhesion to human intestinal Caco-2 cells. An intervention study was conducted in a single-blind, random, and placebo-controlled trial. Twenty-four healthy volunteers were randomly assigned to one of three treatment groups, one provided with the placebo powder excluding the probiotic, one with 3 g of PROBIO-C with a targeted dose of 1.5 × 10 11 CFU of probiotic bacteria, and one with 6 g of PROBIO-C with a targeted dose of 3 × 10 11 CFU of probiotic bacteria. The experiment comprised three phases: the control period (week 1) during which no supplementation was given; the test period (weeks 2-4) during which volunteers were given either the placebo sample or PROBIO-C each day; the post-test period (week 5) during which no supplementation was given. The faecal samples were collected once every week throughout the study. The abundances of Bifidobacterium and Lactobacillus species increased significantly during the test period in both PROBIO-C supplemented groups. In addition, the probiotic supplementation did not result in any significant change in clinical chemistry and haematological parameters. The results from this pilot study indicated that PROBIO-C is well-tolerated and safe.

show abstract

Section: Parameter † Baselinesupporting

confidence: 54%

Effects of a probiotic preparation on the human faecal microflora and biochemical and haematological parameters

Lan

Hsieh²,

Tsai

et al. 2015

ScienceAsia

View full text Add to dashboard Cite

show abstract

“…Placebo-controlled studies have shown that patients using various probiotic mixtures (including B. lactis) have a significantly greater number of improvements in stool consistency (12,13) and in IBS symptoms such as abdominal pain (12,14,15) satisfaction with bowel habits, quality of life (14), and fullness (13,15) than those in the control groups. Furthermore, these studies have shown that a significantly greater number of patients in the probiotic groups had full recovery when compared to the placebo groups (12,13). Patients taking probiotics did not have any significant increases in intestinal microbiota or changes in levels of the inflammatory marker C-reactive protein (15).…”

Section: Discussionmentioning

confidence: 99%

“…According to a recent review and the latest probiotic and prebiotic guidelines published by the World Gastroenterology Organization, B. infantis is the only recommended Bifidobacterium species used in IBS treatment (19). Studies on bifidobacteria generally use probiotic mixtures, and few studies used bifidobacteria alone (12,18). In our study, we used B. lactis B94 as a probiotic and inulin as a prebiotic for the treatment of IBS to investigate the efficacy of synbiotic, probiotic, and prebiotic treatments for IBS.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial

Baştürk

Artan²,

Yılmaz³

2020

Turk J Gastroenterol

View full text Add to dashboard Cite

“…In recent studies, it was shown that 4-week treatment with probiotics improved IBS symptoms and altered composition of the microbiota, and that probiotic treatment in IBS patients reduced the genus Bacteroids to the levels of healthy controls and also improved IBS symptoms. 7,8 However, in other study Lactobacillus plantarum MF1298 species had aggravated IBS symptom score, and this means not all strains with in vitro demonstrated probiotics actually showed therapeutic effects on the in vivo condition. 9 To date, clinical research with probiotics in IBS patients suffered from methodological limitations such as differences in study design, type of probiotics administered, and outcome parameters.…”

Section: Commentsmentioning

confidence: 99%

What Is the Therapeutic Mechanism of the Probiotics in Irritable Bowel Syndrome Patients With Visceral Hypersensitivity?

Kim

2014

J Neurogastroenterol Motil

View full text Add to dashboard Cite

SummaryIrritable bowel syndrome (IBS) is characterized by heterogeneous pathogenesis and many IBS patients suffer from visceral hypersensitivity. Visceral hypersensitivity is evaluated under stimulated condition with mechanical distension using barostat to provide sensations of discomfort or visceral pain in most clinical researches. Distensions administered to rectum using the barostat, can induce visceral discomfort or pain, which are like typical symptoms for IBS. In addition, increased rectal sensitivity has found to be related to symptom severity in daily life. It is known that visceral hypersensitivity was associated with increased intestinal permeability and inflammation. Increased intestinal permeability leads to translocation of bacteria and their products, resulting to induce hypersensitivity by targeting the enteric neurons. Increased release of immunologic mediators resulted in visceral hypersensitivity via sensitization of neuronal cells.Previous studies with probiotic therapeutic effects have focus on daily symptoms in IBS patients, and the effects were a small but significant improvement in overall symptom score. However, in previous studies, heterogeneous groups of IBS patients have been included rather than a selection of IBS patients based on pathophysiological characteristics. None of the studies up to now has chosen an approach by evaluating effects of probiotics targeting on one common pathophysiological mechanism. In this study, Ludidi et al 1 investigated that whether implementing probiotics in IBS patients with documented visceral hypersensitivity had potential effect to reduce visceral hypersensitivity (primary end point).This study was performed a randomized, placebo-controlled, double-blind trial in 40 Rome III IBS patients with visceral hypersensitivity. Prior to participation, patients kept a 2-weak symptom diary and underwent barostat measurement. When visceral hypersensitivity was confirmed, patients were enrolled this study and received a multispecies probiotics (6 different probiotic strains 10 9 CFU/g), or a placebo products of one sachet (5 g) per day for 6 weeks. At the end of the intervention period, visceroperception and symptoms were reevaluated. In total, 35 patients were completed the study (19 in pro-

show abstract

Effect of multispecies probiotics on irritable bowel syndrome: A randomized, double‐blind, placebo‐controlled trial

Abstract: Multispecies probiotics are effective in IBS patients and induce the alterations in the composition of intestinal microbiota.

Cited by 139 publications

References 41 publications

Effects of a probiotic preparation on the human faecal microflora and biochemical and haematological parameters

Effects of a probiotic preparation on the human faecal microflora and biochemical and haematological parameters

Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial

What Is the Therapeutic Mechanism of the Probiotics in Irritable Bowel Syndrome Patients With Visceral Hypersensitivity?

Contact Info

Product

Resources

About